Analysis of Dosage Mutation in PARK2 among Korean Patients with Early-Onset or Familial Parkinson's Disease

Background and Purpose There is some controversy regarding heterozygous mutations of the gene encoding parkin (PARK2) as risk factors for Parkinson's disease (PD), and all previous studies have been performed in non-Asian populations. Dosage mutation of PARK2, rather than a point mutation or small insertion/deletion mutation, was reported to be a risk factor for familial PD; dosage mutation of PARK2 is common in Asian populations. Methods We performed a gene-dosage analysis of PARK2 using real-time polymerase chain reaction for 189 patients with early-onset PD or familial PD, and 191 control individuals. In the case of PD patients with heterozygous gene-dosage mutation, we performed a sequencing analysis to exclude compound heterozygous mutations. The association between heterozygous mutation of PARK2 and PD was tested. Results We identified 22 PD patients with PARK2 mutations (11.6%). Five patients (2.6%) had compound heterozygous mutations, and 13 patients (6.9%) had a heterozygous mutation. The phase could not be determined in one patient. Three small sequence variations were found in 30 mutated alleles (10.0%). Gene-dosage mutation accounted for 90% of all of the mutations found. The frequency of a heterozygous PARK2 gene-dosage mutation was higher in PD patients than in the controls. Conclusions Heterozygous gene-dosage mutation of PARK2 is a genetic risk factor for patients with early-onset or familial PD in Koreans.

[1]  Vincenzo Bonifati,et al.  The genetics of Parkinson's disease: Progress and therapeutic implications , 2013, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Seong,et al.  Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early‐onset Parkinson disease , 2012, Clinical genetics.

[3]  P. Chan,et al.  Parkin dosage mutations in patients with early-onset sporadic and familial Parkinson's disease in Chinese: An independent pathogenic role , 2010, Brain Research.

[4]  G. Schellenberg,et al.  A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2 , 2010, Neurology.

[5]  W. Luo,et al.  Mutation analysis of parkin and PINK1 genes in early-onset Parkinson's disease in China , 2010, Neuroscience Letters.

[6]  B. Tang,et al.  Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism , 2010, Journal of Neurology.

[7]  T Revesz,et al.  A clinico-pathological study of subtypes in Parkinson's disease. , 2009, Brain : a journal of neurology.

[8]  K. Marder,et al.  Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations , 2009, Neurology.

[9]  N. Brüggemann,et al.  Frequency of heterozygous Parkin mutations in healthy subjects: need for careful prospective follow-up examination of mutation carriers. , 2009, Parkinsonism & related disorders.

[10]  A. Brice,et al.  Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.

[11]  Sonja W. Scholz,et al.  Parkin and PINK1 mutations in early-onset Parkinson’s disease: comprehensive screening in publicly available cases and control , 2009, Journal of Medical Genetics.

[12]  K. Xia,et al.  Mutation analysis of Parkin, PINK1, DJ‐1 and ATP13A2 genes in Chinese patients with autosomal recessive early‐onset Parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.

[13]  Y. Sohn,et al.  Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease , 2008, Neurogenetics.

[14]  A. Dürr,et al.  Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls , 2007, Journal of Medical Genetics.

[15]  G. Schellenberg,et al.  Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients , 2007, Annals of neurology.

[16]  C. Ki,et al.  Clinical features and gene analysis in Korean patients with early-onset Parkinson disease. , 2006, Archives of neurology.

[17]  K. Marder,et al.  Case-control study of the parkin gene in early-onset Parkinson disease. , 2006, Archives of neurology.

[18]  K. Marder,et al.  Distribution, type, and origin of Parkin mutations: Review and case studies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[19]  M. Farrer,et al.  Parkin variants in North American Parkinson's disease: Cases and controls , 2003, Movement disorders : official journal of the Movement Disorder Society.

[20]  Y. Agid,et al.  Parkin mutations are frequent in patients with isolated early-onset parkinsonism. , 2003, Brain : a journal of neurology.

[21]  L. Seeberger,et al.  Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease , 2003, Neurology.

[22]  K. Marder,et al.  Evaluation of 50 probands with early-onset Parkinson’s disease for Parkin mutations , 2002, Neurology.

[23]  Andrew J. Lees,et al.  Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.

[24]  A. Lang,et al.  The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. , 2001, Human molecular genetics.

[25]  X. Breakefield,et al.  Parkin deletions in a family with adult‐onset, tremor‐dominant parkinsonism: Expanding the phenotype , 2000, Annals of neurology.

[26]  A. Verma.  Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease: The GenePD Study , 2007 .

[27]  M. Farrer,et al.  Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. , 2005, Archives of neurology.

[28]  K. Marder,et al.  The parkin gene is not involved in late-onset Parkinson's disease. , 2002, Neurology.

[29]  HOMAS,et al.  ASSOCIATION BETWEEN EARLY-ONSET PARKINSON ’ S DISEASE AND MUTATIONS IN THE PARKIN GENE , 2000 .